logo-loader
viewBioSig Technologies, Inc.

BioSig and subsidiary ViralClear enroll patients at four sites for coronavirus trial of merimepodib

The company expects to report results from the study later this summer

Coronavirus graphic
Merimepodib is meant to be orally administered and has demonstrated broad-spectrum in-vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures

BioSig Technologies Inc (NASDAQ:BSGM) announced Monday the enrollment of patients for its Phase 2 trial of merimepodib, a drug candidate for the treatment of the coronavirus.

BioSig, along with its subsidiary ViralClear Pharmaceuticals Inc, enrolled patients at trial sites in Austin, Texas; Rochester, Minnesota; Jacksonville, Florida; and Scottsdale, Arizona. 

The company expects to report results later this summer.

READ: BioSig Technologies set to conduct business with federal government as it applies for SAM registration

"Three of our four trial sites where our partners are enrolling patients are in the recognized hot spots of Texas, Arizona, and Florida,” CEO Kenneth Londoner said in a statement. “The patients in this trial are hospitalized and requiring oxygen; therefore, providing effective treatment is of the utmost importance to all.”

Merimepodib is meant to be orally administered and has demonstrated broad-spectrum in-vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. The study will be randomized, double blind and treat adult patients with advanced cases of the coronavirus. 

BioSig, based in Connecticut, is also commercializing a proprietary biomedical processing platform designed to improve signal fidelity and uncover the full range of electrocardiogram (ECG) and intracardiac signals.

Its first product, PURE EP System, is intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: BioSig Technologies, Inc.

Price: 7.43 USD

NASDAQ:BSGM
Market: NASDAQ
Market Cap: $210.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

BioSig Technologies forms Scientific Advisory Board by adding industry veterans

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive its subsidiary ViralClear Pharmaceuticals Inc has formed its Scientific Advisory Board with two industry veterans experienced as both regulators and corporate executives. Londoner adds what's more, the group adopted a...

2 weeks, 6 days ago

2 min read